Last update: June 27, 2021
Minimal risk for breastfeeding and infant.
Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID).
Oral, rectal, intramuscular, intravenous and topical administration every 6 to 12 hours.
It is excreted in breastmilk in clinically negligibe amounts (Jacqz-Aigrain 2007) and authors consider it compatible with breastfeeding (Davanzo 2014, Jacqz-Aigrain 2007, Janssen 2000, Nice 2000).
Its high percentage of protein binding explains the very small transfer to milk observed.
In a French pharmacovigilance study, several possible cases, unconfirmed, were found of the implication of ketoprofen in certain adverse effects in the infant (Soussan 2014). Its pharmacokinetics makes its involvement unlikely.
The small dose and the low plasma absorption of most topical dermatological preparations make transfer to breastmilk in significant amounts unlikely. Systemic bioavailability is 5% (AEMPS 2016).
Most non-steroidal anti-inflammatories may increase jaundice, so it is preferable to avoid them during the neonatal period in mothers of infants with jaundice. (Janssen 2000).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM